Business
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17,
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased\nSOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction were presented by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF in a Late Breaking Clinical Trial session at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) and were simultaneously published in the Journal of the American College of Cardiology.1 “These results build on our previous observation that the treatment effect of omecamtiv mecarbil grows progressively stronger in patients with lower ejection fraction, the very patients who are at the highest risk for heart failure hospitalization and cardiovascular death,” said John Teerlink, M.D. “Given that these severe heart failure patients are often unable to tolerate guideline-directed medical therapy and are left with few treatment options, omecamtiv mecarbil may provide an opportunity to improve their systolic function and keep them out of the hospital. In addition, omecamtiv mecarbil has no adverse effect on heart rate, blood pressure, kidney function or blood potassium levels, suggesting it can be added without interfering with guideline-directed medical therapy.” “Despite excellent background therapy, heart failure patients are still in need of additional options as evidenced by the increasingly high event rates as baseline ejection fraction falls,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “The data presented today underscore the potential value that omecamtiv mecarbil may have in reducing the clinical and economic burden of severe heart failure. We look forward to further analyses of GALACTIC-HF in the coming months and to advancing toward our goal of an NDA submission in the U.S. for omecamtiv mecarbil in the second half of 2021.”...